NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD)

Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.

Never miss a new study

Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear

Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Gene therapy injection shows promise for blinding eye disease

Disease control Completed

This early-stage study tested a new gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration, a leading cause of vision loss. The treatment aims to block abnormal blood vessel growth and leakage in the eye. The main goal was to check if the therapy is…

Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD)

Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control

Last updated Apr 26, 2026 19:38 UTC

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD)

Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear

Gene therapy injection shows promise for blinding eye disease